OFFER TECHNO

HuMoSC: Human Monocyte-derived Suppressor Cells

GvHD / transplantation / autoimmunity / inflammation



CONTEXT

Current treatments for Graft versus Host Disease (GvHD) are based on immunosuppressive drugs; however, those are efficient only in about 50% of the patients and are associated with severe infections.
Cell therapies belong to emerging strategies to prevent lethal GvHD; nevertheless, current cells therapies are negatively affected by the patient inflammatory state and may promote tumor growth.

DESCRIPTION

In order to avoid the issues of current therapies, we have developed a novel cellular therapy capable to act on such mortality/morbidity-associated disease such as GvHD.
Our unique approach originates in *ex vivo* generation of human suppressor cell subpopulation of monocytic origin, the HuMoSC. HuMoSC induce and maintain immune tolerance in hematopoietic stem-cell transplantation thus preventing lethal GvHD.
HuMoSC significant efficiency and mechanism of action has potential for further applications in solid organ transplantation and autoimmune disorders.

COMPETITIVE ADVANTAGES

- **Significant GvHD prevention**
- **Can be generated from autologous or allogenic sources**
- **Immunomodulating action (no complete immuno-suppression as with immunosuppressive drugs)**
- **Efficacy not altered under inflammatory conditions or in presence of immunosuppressive drugs *in vitro***
- **Easy to generate and ready for use in clinical trials**
- **Very stable and can be cryopreserved**

Markets & applications

Pharmaceutical - cell therapy :

- GvHD Prevention
- Graft rejection
- Autoimmune diseases

Development stage

- **Efficacy validated in a preclinical humanized mouse model**
- **Mechanism of action largely elucidated**

Research team

Laboratory "Interactions Hôte-Greffon-Tumeur & Ingénierie Cellulaire et Génique"
INSERM - UBFC

Intellectual property

French patent application (March 19th, 2014) and PCT application (WO2015140077)

Target partnership

Patent licensing or co-development

CONTACT-US

Daniel KIRCHHERR
Business Development Manager
+33 (0)7 76 16 66 90
daniel.kirchherr@sayens.fr

SAYENS SATT

FIND OUT OUR TECHNOLOGICAL OFFERS
www.sayens.fr